Obgemsa (Vibegron) film-coated tablets

Obgemsa is a prescription medication containing the active ingredient Vibegron, used primarily to treat overactive bladder. The brand was originally developed by the Japanese pharmaceutical company Urovant Sciences, which was later acquired and integrated into the broader structure of Sumitomo Pharma. It is part of a new generation of beta-3 adrenergic agonists designed to improve bladder control.

While the drug was originally a Japanese innovation, its manufacturing takes place globally to meet demand in various markets, including North America and Europe. The brand is currently managed by Pierre Fabre in several European territories, including Germany, through licensing agreements. The ultimate owner remains the Sumitomo Pharma group, based in Japan, which oversees the global development and strategic distribution of the therapeutic brand.